Hepatitis C: Changing genotype distribution with important implications for patient management

Netherlands Journal of Medicine

Volumn 64, Issue 4, 2006, Pages 96-99

  van Soest, H ^a   Boland, G J ^a   van Erpecum, K J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Genotype distribution; Hepatitis C; Treatment responses

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; INDIVIDUALIZATION; NETHERLANDS; NONHUMAN; PHARMACOGENETICS; PREVALENCE; SEQUENCE ANALYSIS; SHORT COURSE THERAPY; VIRUS CARRIER;

ANTIVIRAL AGENTS; CHRONIC DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; NETHERLANDS; RNA, VIRAL;

EID: 33645931965     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8):556-62.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 suppl 1):S35-46.
3. Health Council of the Netherlands: Committee on hepatitis C. Detection and treatment of people with Hepatitis C. 1997. Ref Type: Report.
4. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31(suppl 1):3-8.
5. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343-50.
6. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41(1):48-54.
7. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74(Pt 11):2391-9.
8. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962-73.
9. De Vries MJ, te Rijdt B, van Nieuwkerk CMJ. Genotype distribution amongst hepatitis C patients in the Netherlands. Neth J Med 2006;64(4):109-13.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
12. El Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005;100(11):2447-52.
13. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54(6):858-66.
14. Heathcote J, Zeuzem S. Pegylated interferon monotherapy for chronic hepatitis C. Semin Liver Dis 2004;24(suppl 2):39-45.
15. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31(1):211-8.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38(3):645-52.
17. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43(3):425-33.
18. Wong JB, Davis GL, McHutchison JC, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003;98(11):2354-62.
19. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55.
20. Zeuzem S, Huitcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993-9.
21. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129(2):522-7.
22. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609-17.
23. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44(1):97-103.
24. Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW. The treatment of hepatitis C: history, presence and future. Neth J Med 2004;62(3):76-82.
25. De Knegt RJ. Behandeling van Hepatitis C: het kan korter! Lever, Nieuwsbulletin van de Nederlandse Vereniging voor Hepatologie 2005;29(4):11-2.
26. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32(4):884-92.
27. Kleter GE, van Doom LJ, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. Sequence analysis of the 5′ untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol 1994;32(2):306-10.
28. Schneeberger PM, Keur I, van der Vliet W, et al. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998;36(6):1711-5.